Who Paid My Doc
Jonathan Yerasimides
Orthopaedic Surgery Louisville, KY Medical Doctor
NPI 1295763225 CMS profile 58066
9880 Angies Way, Suite 250, Louisville, KY 40241
General payments
$4,272,197
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$10,203
Through program year 2025, Jonathan Yerasimides of Louisville, KY is reported in the CMS Open Payments database as having received $4,272,197 across 1,455 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,203 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $369,739 | 180 | |
| 2024 | General | $1,925,722 | 185 | |
| 2023 | General | $602,725 | 197 | |
| 2022 | General | $475,011 | 198 | |
| 2021 | General | $417,841 | 265 | |
| 2020 | General | $240,577 | 203 | |
| 2019 | General | $240,581 | 227 |
Beside peers
- Jonathan Yerasimides
- Orthopaedic Surgery median
- Middle half of Orthopaedic Surgery
- National median
In program year 2025, general payments to Jonathan Yerasimides were reported at $369,739. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.
Show as a table
| Year | Jonathan Yerasimides | Orthopaedic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $240,581 | $644 | $140–$2,844 | $163 |
| 2020 | $240,577 | $312 | $75–$1,860 | $114 |
| 2021 | $417,841 | $520 | $117–$2,495 | $132 |
| 2022 | $475,011 | $598 | $128–$2,731 | $149 |
| 2023 | $602,725 | $461 | $128–$2,264 | $160 |
| 2024 | $1,925,722 | $497 | $134–$2,475 | $164 |
| 2025 | $369,739 | $563 | $147–$2,717 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
2,214
Drug cost
$29,738
Branded share of claims
27.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Tranexamic Acid | Generic | 364 | $9,584 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 505 | $7,344 | |
| Celecoxib | Generic | 119 | $3,824 | |
| Mupirocin | Generic | 415 | $2,161 | |
| Diclofenac Sodium | Generic | 205 | $2,161 | |
| Doxycycline Monohydrate | Generic | 110 | $1,465 | |
| Ondansetron Odt Ondansetron | Brand | 44 | $668 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 59 | $566 | |
| Methylprednisolone | Generic | 83 | $455 | |
| Pregabalin | Generic | 29 | $381 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 22 billing codesPaid by Medicare
$409,011
Medicare patients
789
Services billed
2,730
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 69% | |
| Ischemic heart disease | 24% | |
| Diabetes | 20% | |
| Depression | 18% | |
| Atrial fibrillation | 17% | |
| Chronic kidney disease | 14% | |
| Cancer | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 63 | 321 | $244 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1,455 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Surgery in Kentucky
Arthur Malkani
Orthopaedic Surgery · Louisville, KY
John Lewis
Orthopaedic Surgery · Louisville, KY
Akbar Nawab
Orthopaedic Surgery · Louisville, KY
Samer Hasan
Orthopaedic Surgery · Crestview Hills, KY
Phillip Singer
Orthopaedic Surgery · Bowling Green, KY
Brent Morris
Orthopaedic Surgery · Lexington, KY
Related records
Orthopaedic Surgery in Kentucky
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Kentucky
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.